Jeremy Bastid, auteur sur Orega Biotech https://www.orega-biotech.com/author/oregadmin/ Fri, 21 Jun 2024 13:41:55 +0000 en-US hourly 1 CICON 2024 https://www.orega-biotech.com/news/cicon-2024/ Fri, 21 Jun 2024 13:33:46 +0000 https://www.orega-biotech.com/?p=3599 Jeremy BASTID, CEO of OREGA Biotech, will attend the upcoming CICON24 meeting to be held at the Gaylord National Resort & Convention Center in National Harbor, MD (Washington, DC area) September 8-11, 2024.

L’article CICON 2024 est apparu en premier sur Orega Biotech.

]]> Jeremy BASTID, CEO of OREGA Biotech, will attend the upcoming CICON24 meeting to be held at the Gaylord National Resort & Convention Center in National Harbor, MD (Washington, DC area) September 8-11, 2024.

L’article CICON 2024 est apparu en premier sur Orega Biotech.

]]> First patient dosed in phase 2 MATISSE trial of IPH5201 https://www.orega-biotech.com/news/first-patient-dosed-in-phase-2-matisse-trial-of-iph5201/ Mon, 26 Jun 2023 08:00:23 +0000 https://www.orega-biotech.com/?p=3575 Lyon, France, June 26th, 2023 – OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, reported today that the first patient was dosed in MATISSE, a Phase 2 multicenter single-arm study (NCT05742607) evaluating neoadjuvant and adjuvant treatment with IPH5201, an anti-CD39 blocking monoclonal antibody, in combination with durvalumab (anti-PD-L1) and chemotherapy, in treatment-naïve patients with resectable early stage non-small cell lung cancer (NSCLC). The Press Release was issued by the study sponsor, Innate Pharma, and can be accessed on the company’s website. About IPH5201 antibody IPH5201 is a humanized CD39 blocking antibody codeveloped by Innate Pharma and AstraZeneca (AZ). OREGA Biotech entered into an exclusive and worldwide License Agreement with Innate Pharma in 2016. The lead antibody (IPH5201) has been further partnered with AstraZeneca in 2018. AstraZeneca conducted a multicenter, open-label, dose-escalation Phase 1 trial in advanced solid tumors (NCT04261075) with IPH5201 alone or in combination with durvalumab (anti PD-L1 antibody). About NCT05742607 clinical trial MATISSE is a Phase 2 multicenter single-arm study (NCT05742607) evaluating neoadjuvant and adjuvant treatment with IPH5201 in combination with durvalumab (anti-PD-L1, AZ) and chemotherapy in treatment-naïve patients with resectable early-stage non-small cell lung cancer (NSCLC). The primary objectives of the study are to assess antitumor activity of neoadjuvant treatment based on pathological complete response (pCR) and safety. More information on the Phase 2 clinical trial is accessible online. About OREGA Biotech OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. Our in vivo screening platform aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our business strategy is to establish preclinical proof of concept with new targets prior to enter into early-stage partnership or license agreements with larger biotech or pharmaceutical companies. The company is managed by Jeremy Bastid, CEO and Gilles Alberici, President. Contact Jeremy Bastid, Chief Executive Officer Tel.: +33 (0)4 37 49 87 20 Email : jeremy.bastid@orega-biotech.com  

L’article First patient dosed in phase 2 MATISSE trial of IPH5201 est apparu en premier sur Orega Biotech.

]]> Lyon, France, June 26th, 2023 – OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, reported today that the first patient was dosed in MATISSE, a Phase 2 multicenter single-arm study (NCT05742607) evaluating neoadjuvant and adjuvant treatment with IPH5201, an anti-CD39 blocking monoclonal antibody, in combination with durvalumab (anti-PD-L1) and chemotherapy, in treatment-naïve patients with resectable early stage non-small cell lung cancer (NSCLC).
The Press Release was issued by the study sponsor, Innate Pharma, and can be accessed on the company’s website.

About IPH5201 antibody
IPH5201 is a humanized CD39 blocking antibody codeveloped by Innate Pharma and AstraZeneca (AZ).
OREGA Biotech entered into an exclusive and worldwide License Agreement with Innate Pharma in 2016. The lead antibody (IPH5201) has been further partnered with AstraZeneca in 2018. AstraZeneca conducted a multicenter, open-label, dose-escalation Phase 1 trial in advanced solid tumors (NCT04261075) with IPH5201 alone or in combination with durvalumab (anti PD-L1 antibody).

About NCT05742607 clinical trial
MATISSE is a Phase 2 multicenter single-arm study (NCT05742607) evaluating neoadjuvant and adjuvant treatment with IPH5201 in combination with durvalumab (anti-PD-L1, AZ) and chemotherapy in treatment-naïve patients with resectable early-stage non-small cell lung cancer (NSCLC). The primary objectives of the study are to assess antitumor activity of neoadjuvant treatment based on pathological complete response (pCR) and safety. More information on the Phase 2 clinical trial is accessible online.

About OREGA Biotech
OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. Our in vivo screening platform aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our business strategy is to establish preclinical proof of concept with new targets prior to enter into early-stage partnership or license agreements with larger biotech or pharmaceutical companies. The company is managed by Jeremy Bastid, CEO and Gilles Alberici, President.

Contact
Jeremy Bastid, Chief Executive Officer
Tel.: +33 (0)4 37 49 87 20
Email : jeremy.bastid@orega-biotech.com

 

L’article First patient dosed in phase 2 MATISSE trial of IPH5201 est apparu en premier sur Orega Biotech.

]]> AACR annual meeting 2023 https://www.orega-biotech.com/news/aacr-annual-meeting-2023/ Mon, 10 Apr 2023 07:00:11 +0000 https://www.orega-biotech.com/?p=3570 Jeremy BASTID, CEO of OREGA Biotech, will attend the upcoming AACR annual meeting to be held on April 14 – 19, 2023 in Orlando, Florida.

L’article AACR annual meeting 2023 est apparu en premier sur Orega Biotech.

]]> Jeremy BASTID, CEO of OREGA Biotech, will attend the upcoming AACR annual meeting to be held on April 14 – 19, 2023 in Orlando, Florida.

L’article AACR annual meeting 2023 est apparu en premier sur Orega Biotech.

]]> IPH5201 (CD39 mAb): initiation of Phase 2 clinical trial MATISSE https://www.orega-biotech.com/news/initiation-of-phase-2-trial-matisse/ Fri, 24 Feb 2023 08:11:31 +0000 https://www.orega-biotech.com/?p=3551 Lyon, France, February 24th, 2023 – OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, today announces the initiation of IPH5201 CD39 blocking antibody phase 2 trial (MATISSE). The study entitled “Phase II Multicenter, Open Label, Non-randomized Study of Neoadjuvant and Adjuvant Treatment With IPH5201 and Durvalumab in Patients With Resectable, Early-stage (II to IIIA) Non-Small Cell Lung Cancer (MATISSE)” is an open-label, single-arm multicenter study (NCT05742607). As announced in 2022 (press release), the study will enroll 70 patients treated with IPH5201 (CD39 antibody) and Durvalumab (PDL1 antibody) plus standard of care chemotherapy before surgery followed by IPH5201 and Durvalumab. About IPH5201 antibody IPH5201 is a humanized CD39 blocking antibody. OREGA Biotech entered into an exclusive and worldwide License Agreement with Innate Pharma in 2016. The lead antibody has been further partnered with AstraZeneca in 2018. AstraZeneca conducted a multicenter, open-label, dose-escalation Phase 1 trial in advanced solid tumors (NCT04261075) with IPH5201 alone or in combination with durvalumab (anti PD-L1 antibody). About OREGA Biotech OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. Our in vivo screening platform aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our business strategy is to establish preclinical proof of concept with new targets prior to enter into early-stage partnership or license agreements with larger biotech or pharmaceutical companies. The company is managed by Jeremy Bastid, CEO and Gilles Alberici, President. Contact Jeremy Bastid, Chief Executive Officer Tel.: +33 (0)4 37 49 87 20 Email : jeremy.bastid@orega-biotech.com

L’article IPH5201 (CD39 mAb): initiation of Phase 2 clinical trial MATISSE est apparu en premier sur Orega Biotech.

]]> Lyon, France, February 24th, 2023 – OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, today announces the initiation of IPH5201 CD39 blocking antibody phase 2 trial (MATISSE). The study entitled “Phase II Multicenter, Open Label, Non-randomized Study of Neoadjuvant and Adjuvant Treatment With IPH5201 and Durvalumab in Patients With Resectable, Early-stage (II to IIIA) Non-Small Cell Lung Cancer (MATISSE)” is an open-label, single-arm multicenter study (NCT05742607). As announced in 2022 (press release), the study will enroll 70 patients treated with IPH5201 (CD39 antibody) and Durvalumab (PDL1 antibody) plus standard of care chemotherapy before surgery followed by IPH5201 and Durvalumab.

About IPH5201 antibody

IPH5201 is a humanized CD39 blocking antibody. OREGA Biotech entered into an exclusive and worldwide License Agreement with Innate Pharma in 2016. The lead antibody has been further partnered with AstraZeneca in 2018. AstraZeneca conducted a multicenter, open-label, dose-escalation Phase 1 trial in advanced solid tumors (NCT04261075) with IPH5201 alone or in combination with durvalumab (anti PD-L1 antibody).

About OREGA Biotech

OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. Our in vivo screening platform aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our business strategy is to establish preclinical proof of concept with new targets prior to enter into early-stage partnership or license agreements with larger biotech or pharmaceutical companies. The company is managed by Jeremy Bastid, CEO and Gilles Alberici, President.

Contact

Jeremy Bastid, Chief Executive Officer

Tel.: +33 (0)4 37 49 87 20

Email : jeremy.bastid@orega-biotech.com

L’article IPH5201 (CD39 mAb): initiation of Phase 2 clinical trial MATISSE est apparu en premier sur Orega Biotech.

]]> Happy holidays and Merry Christmas ! https://www.orega-biotech.com/news/happy-holidays-and-merry-christmas/ Fri, 23 Dec 2022 11:05:48 +0000 https://www.orega-biotech.com/?p=3545 The OREGA Biotech team wishes you all a wonderful holiday season, a Merry Christmas and a healthy and successful new year !

L’article Happy holidays and Merry Christmas ! est apparu en premier sur Orega Biotech.

]]> The OREGA Biotech team wishes you all a wonderful holiday season, a Merry Christmas and a healthy and successful new year !

L’article Happy holidays and Merry Christmas ! est apparu en premier sur Orega Biotech.

]]> OREGA enters into a License Agreement with Genmab https://www.orega-biotech.com/news/orega-license-genmab/ Tue, 06 Dec 2022 06:00:10 +0000 https://www.orega-biotech.com/?p=3496 – PRESS RELEASE – For immediate release OREGA Biotech enters into an Exclusive License Agreement with Genmab for a novel immuno-oncology antibody program   OREGA Biotech grants Genmab rights to its first-in-class antibody against a novel, undisclosed immuno-oncology target Under the License Agreement with OREGA Biotech, Genmab will obtain the exclusive, worldwide right to develop and commercialize novel antibody therapeutics utilizing OREGA Biotech’s first-in-class antibody OREGA Biotech to receive an upfront payment and is eligible to receive development, regulatory and commercial milestone payments along with royalties on commercial sales.   Lyon, France, december 6th, 2022 – OREGA Biotech announces today an exclusive license agreement under which OREGA Biotech grants Genmab full, worldwide rights to its first-in-class immuno-oncology antibody program against a novel and undisclosed target. This license agreement results from a fruitful research collaboration between the two companies initiated in 2020. “We are thrilled to partner with Genmab, the renowned international biotechnology company“, said Jeremy Bastid, Chief Executive Officer of OREGA Biotech. “Our team discovered the role of this novel target in impairing the response to the PD1/PDL1 immune checkpoint inhibitors and demonstrated that a neutralizing antibody could reverse this effect and improve the response to cancer immunotherapy. We have been working very closely with Genmab’s scientific team for more than 2 years and we are convinced that their scientific skills and development capabilities will be of paramount importance to further develop this asset”, he added. Gilles Alberici, President of OREGA Biotech, further commented: “This licensing agreement marks another major step forward for our company and team after the successful out-licensing of our CD39 antibody program which is now entering phase 2 clinical trial. Given the track record of Genmab in developing and delivering innovations to the patients, we believe that Genmab is very well positioned to bring this novel antibody program to the clinic”, he added. Genmab will be responsible for the research, development, manufacturing and commercialization of the antibody. The parties will aim to enter into an additional agreement for OREGA Biotech to support Genmab’s preclinical research activities related to this antibody. “I would like to take the opportunity of this announcement to congratulate our scientists who did a fantastic work in advancing this antibody program and collaborating successfully with our Genmab’s colleagues despite the Covid-19 pandemic. I also would like to thank our partners from Inserm Transfert for their continued support during the licensing process”, Jeremy Bastid […]

L’article OREGA enters into a License Agreement with Genmab est apparu en premier sur Orega Biotech.

]]> – PRESS RELEASE –

For immediate release

OREGA Biotech enters into an Exclusive License Agreement with Genmab for a novel immuno-oncology antibody program

 

  • OREGA Biotech grants Genmab rights to its first-in-class antibody against a novel, undisclosed immuno-oncology target
  • Under the License Agreement with OREGA Biotech, Genmab will obtain the exclusive, worldwide right to develop and commercialize novel antibody therapeutics utilizing OREGA Biotech’s first-in-class antibody
  • OREGA Biotech to receive an upfront payment and is eligible to receive development, regulatory and commercial milestone payments along with royalties on commercial sales.

 

Lyon, France, december 6th, 2022 – OREGA Biotech announces today an exclusive license agreement under which OREGA Biotech grants Genmab full, worldwide rights to its first-in-class immuno-oncology antibody program against a novel and undisclosed target. This license agreement results from a fruitful research collaboration between the two companies initiated in 2020.

“We are thrilled to partner with Genmab, the renowned international biotechnology company“, said Jeremy Bastid, Chief Executive Officer of OREGA Biotech. “Our team discovered the role of this novel target in impairing the response to the PD1/PDL1 immune checkpoint inhibitors and demonstrated that a neutralizing antibody could reverse this effect and improve the response to cancer immunotherapy. We have been working very closely with Genmab’s scientific team for more than 2 years and we are convinced that their scientific skills and development capabilities will be of paramount importance to further develop this asset”, he added.

Gilles Alberici, President of OREGA Biotech, further commented: “This licensing agreement marks another major step forward for our company and team after the successful out-licensing of our CD39 antibody program which is now entering phase 2 clinical trial. Given the track record of Genmab in developing and delivering innovations to the patients, we believe that Genmab is very well positioned to bring this novel antibody program to the clinic”, he added.

Genmab will be responsible for the research, development, manufacturing and commercialization of the antibody. The parties will aim to enter into an additional agreement for OREGA Biotech to support Genmab’s preclinical research activities related to this antibody.

“I would like to take the opportunity of this announcement to congratulate our scientists who did a fantastic work in advancing this antibody program and collaborating successfully with our Genmab’s colleagues despite the Covid-19 pandemic. I also would like to thank our partners from Inserm Transfert for their continued support during the licensing process”, Jeremy Bastid concluded.

Financial Terms

OREGA Biotech will receive an upfront payment and is eligible to receive development, regulatory and commercial milestone payments plus royalties on commercial sales. The financial terms of the agreement have not been disclosed.

Download the press release.

About OREGA Biotech

OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. Our in vivo screening platform aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our business strategy is to establish preclinical proof of concept with new targets prior to enter into early-stage partnership or license agreements with larger biotech or pharmaceutical companies. Our lead asset, an anti-CD39 monoclonal antibody, has been out-licensed to Innate Pharma and then partnered with AstraZeneca. The company is managed by Jeremy Bastid, CEO and Gilles Alberici, President.

Contact

Jeremy Bastid, Chief Executive Officer

Tel.: +33 (0)4 37 49 87 20

Email : jeremy.bastid@orega-biotech.com

L’article OREGA enters into a License Agreement with Genmab est apparu en premier sur Orega Biotech.

]]> 37th SITC annual meeting 2022 https://www.orega-biotech.com/news/aacr-annual-meeting-2021-2-2/ Thu, 20 Oct 2022 16:25:17 +0000 https://www.orega-biotech.com/?p=3473 Jeremy BASTID, CEO of OREGA Biotech, will attend the upcoming 37th SITC annual meeting to be held November 8-12 2022 (Boston, MA & virtual).

L’article 37th SITC annual meeting 2022 est apparu en premier sur Orega Biotech.

]]> Jeremy BASTID, CEO of OREGA Biotech, will attend the upcoming 37th SITC annual meeting to be held November 8-12 2022 (Boston, MA & virtual).

L’article 37th SITC annual meeting 2022 est apparu en premier sur Orega Biotech.

]]> PRESS RELEASE – IPH5201 (CD39 mAb) to advance into Phase 2 https://www.orega-biotech.com/news/iph5201phase2/ Fri, 03 Jun 2022 08:18:13 +0000 https://www.orega-biotech.com/?p=3369 – PRESS RELEASE – For immediate release Progress of OREGA Biotech’s CD39 program: IPH5201 to advance into Phase 2 clinical trial in lung cancer   Lyon, France, June 6th, 2022 – OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, provides an update on its CD39 program: Innate Pharma announced that IPH5201, the CD39 blocking monoclonal antibody developed in collaboration with AstraZeneca, will advance into a Phase 2 clinical trial in lung cancer. About IPH5201 antibody IPH5201 is a humanized CD39 blocking antibody. OREGA Biotech commenced the CD39 program at its inception in 2010, then entered into an exclusive and worldwide License Agreement with Innate Pharma in 2016. The lead antibody has been further partnered with AstraZeneca in 2018. AstraZeneca conducted a multicenter, open-label, dose-escalation Phase 1 trial in advanced solid tumors (NCT04261075) with IPH5201 alone or in combination with durvalumab (anti PD-L1 antibody). Jeremy Bastid, Chief Executive Officer of OREGA Biotech, commented “We are very pleased that IPH5201 antibody is now progressing into a Phase 2 trial; this represents a major achievement for our company. Our academic cofounders are also very proud of having been involved in the discovery of the immunoregulatory role of the adenosine pathway in cancer, the components of which are now being targeted in multiple clinical trials”. Download the Press Release. About OREGA Biotech OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. Our in vivo screening platform aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our business strategy is to establish preclinical proof of concept with new targets prior to enter into early-stage partnership or license agreements with larger biotech or pharmaceutical companies. The company is managed by Jeremy Bastid, CEO and Gilles Alberici, President. Contact Jeremy Bastid, Chief Executive Officer Tel.: +33 (0)4 37 49 87 20 jeremy.bastid@orega-biotech.com   For more information: www.orega-biotech.com

L’article PRESS RELEASE – IPH5201 (CD39 mAb) to advance into Phase 2 est apparu en premier sur Orega Biotech.

]]> – PRESS RELEASE –

For immediate release

Progress of OREGA Biotech’s CD39 program: IPH5201 to advance into Phase 2 clinical trial in lung cancer

 

Lyon, France, June 6th, 2022 – OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, provides an update on its CD39 program: Innate Pharma announced that IPH5201, the CD39 blocking monoclonal antibody developed in collaboration with AstraZeneca, will advance into a Phase 2 clinical trial in lung cancer.

About IPH5201 antibody

IPH5201 is a humanized CD39 blocking antibody. OREGA Biotech commenced the CD39 program at its inception in 2010, then entered into an exclusive and worldwide License Agreement with Innate Pharma in 2016. The lead antibody has been further partnered with AstraZeneca in 2018. AstraZeneca conducted a multicenter, open-label, dose-escalation Phase 1 trial in advanced solid tumors (NCT04261075) with IPH5201 alone or in combination with durvalumab (anti PD-L1 antibody).

Jeremy Bastid, Chief Executive Officer of OREGA Biotech, commented “We are very pleased that IPH5201 antibody is now progressing into a Phase 2 trial; this represents a major achievement for our company. Our academic cofounders are also very proud of having been involved in the discovery of the immunoregulatory role of the adenosine pathway in cancer, the components of which are now being targeted in multiple clinical trials”.

Download the Press Release.

About OREGA Biotech

OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. Our in vivo screening platform aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our business strategy is to establish preclinical proof of concept with new targets prior to enter into early-stage partnership or license agreements with larger biotech or pharmaceutical companies. The company is managed by Jeremy Bastid, CEO and Gilles Alberici, President.

Contact

Jeremy Bastid, Chief Executive Officer

Tel.: +33 (0)4 37 49 87 20

jeremy.bastid@orega-biotech.com

 

For more information: www.orega-biotech.com

L’article PRESS RELEASE – IPH5201 (CD39 mAb) to advance into Phase 2 est apparu en premier sur Orega Biotech.

]]> AACR annual meeting 2022 https://www.orega-biotech.com/news/aacr-annual-meeting-2021-2/ Mon, 04 Apr 2022 12:49:19 +0000 https://www.orega-biotech.com/?p=3365 Jeremy BASTID, CEO of OREGA Biotech, will participate to the upcoming AACR annual meeting to be held on April 9-13 in New Orleans, Louisiana.

L’article AACR annual meeting 2022 est apparu en premier sur Orega Biotech.

]]> Jeremy BASTID, CEO of OREGA Biotech, will participate to the upcoming AACR annual meeting to be held on April 9-13 in New Orleans, Louisiana.

L’article AACR annual meeting 2022 est apparu en premier sur Orega Biotech.

]]> World Cancer Day https://www.orega-biotech.com/news/world-cancer-day/ Fri, 04 Feb 2022 09:50:55 +0000 https://www.orega-biotech.com/?p=3362 Today marks World Cancer Day 2022. With 10 million deaths per year, cancer is the second leading cause of death in the world. At OREGA Biotech we are committed to discover and develop novel cancer immunotherapies. We thank our collaborators and partners with whom we work hard to achieve this goal !

L’article World Cancer Day est apparu en premier sur Orega Biotech.

]]> Today marks World Cancer Day 2022. With 10 million deaths per year, cancer is the second leading cause of death in the world. At OREGA Biotech we are committed to discover and develop novel cancer immunotherapies. We thank our collaborators and partners with whom we work hard to achieve this goal !

L’article World Cancer Day est apparu en premier sur Orega Biotech.

]]>